Growth Metrics

Cytek Biosciences (CTKB) Income towards Parent Company (2020 - 2025)

Cytek Biosciences' Income towards Parent Company history spans 6 years, with the latest figure at -$44.1 million for Q4 2025.

  • For Q4 2025, Income towards Parent Company fell 558.98% year-over-year to -$44.1 million; the TTM value through Dec 2025 reached -$66.5 million, down 992.98%, while the annual FY2025 figure was -$66.5 million, 1005.3% down from the prior year.
  • Income towards Parent Company reached -$44.1 million in Q4 2025 per CTKB's latest filing, down from -$5.5 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of $9.6 million in Q4 2024 to a low of -$44.1 million in Q4 2025.
  • Average Income towards Parent Company over 5 years is -$4.0 million, with a median of -$1.7 million recorded in 2021.
  • The largest YoY upside for Income towards Parent Company was 419.14% in 2022 against a maximum downside of 2215.69% in 2022.
  • A 5-year view of Income towards Parent Company shows it stood at -$1.2 million in 2021, then soared by 419.14% to $3.7 million in 2022, then skyrocketed by 48.01% to $5.5 million in 2023, then soared by 74.5% to $9.6 million in 2024, then tumbled by 558.98% to -$44.1 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Income towards Parent Company are -$44.1 million (Q4 2025), -$5.5 million (Q3 2025), and -$5.6 million (Q2 2025).